What can be achieved?
Distribution & Quantification of a drug candidate and its metabolites in brain substructures
Better lead selection in comparing drug penetration with targets within the brain substructures and receptors
Quantification of drugs and metabolites in different layers of the brain
Better toxicity assessment with identification of the possible causes of toxicity in the brain
Drug quantification combined with Biomarker imaging (Beta Amyloid 1-42, 1-38…)
What are our advantages?
Quantify drug and metabolites in different region of the brain
Ability to overlay both molecular and spatial information within multimodal platform and software (IHC, MSI, etc…)
Efficacy and Safety Biomarkers monitoring thanks to a global approach
High Resolution Mass Spectrometers (R>200,000)
Where can we work?
- Corpus callosum
- Blood-brain barrier
Specific MALDI-MSI: Tag-Mass
By Jonathan Stauber, ImaBiotech’s President